USPTO Examiner PHAN DOAN THI THUC - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18736621TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGSJune 2024September 2025Abandon1510NoNo
18594231OCULAR LUBRICANT FORMULATIONSMarch 2024August 2025Allow1710NoNo
18575483CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICSDecember 2023February 2025Allow1411NoNo
18514612TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD)November 2023August 2025Abandon2010NoNo
18499240ASTAXANTHIN PICKERING EMULSION WITH COLON TARGETED DELIVERY FUNCTION, AND PREPARATION METHOD AND APPLICATION METHOD THEREOFNovember 2023October 2024Abandon1220NoNo
18385805Method of Dispersing Hydrophobic Substances in Aqueous Cleansing SystemOctober 2023February 2026Allow2730YesNo
183799646'-(3-CHLOROPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSOctober 2023January 2024Allow310NoNo
18463734COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKINSeptember 2023November 2024Abandon1401NoNo
18462245AGOMELATINE ORAL TRANSMUCOSAL FILMSeptember 2023January 2024Allow510YesNo
18278726HAIR GROWTH AGENTAugust 2023February 2026Abandon3001NoNo
18235256SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODSAugust 2023December 2024Abandon1610NoNo
18449747SEMI-SOLID TOPICAL COMPOSITION CONTAINING PIRFENIDONE AND MODIFIED DIALLYL DISULFIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNEAugust 2023June 2025Abandon2220NoNo
18208279Crushable Capsule Beads Containing Cuticle Moisturizing OilsJune 2023January 2026Abandon3110NoNo
18208186USE OF SODIUM THIOSULFATE (STS) WITH AND WITHOUT COFACTORS FOR THE TREATMENT OF INFLAMMATORY, NEURODEGENERATIVE AND NEUROPSYCHIATRIC CONDITIONSJune 2023December 2024Abandon1840NoNo
18140124SLURRY AND SOLUTION COMPOSITIONSApril 2023June 2024Abandon1410NoNo
18308409ANTIMICROBIAL COATINGS FOR MEDICAL DEVICESApril 2023November 2024Abandon1910NoNo
18033087PROCESS FOR PRODUCING MICROPARTICLES LADEN WITH AN AROMA CHEMICALApril 2023March 2026Abandon3411NoNo
18134687TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGSApril 2023June 2024Abandon1410NoNo
18131871PYRACLOSTROBIN MICROCAPSULE BASED ON SODIUM ALGINATE AND PREPARATION METHODApril 2023November 2023Allow720YesNo
18174233Organic CompoundsFebruary 2023June 2025Abandon2821NoNo
18100104ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIBJanuary 2023October 2024Abandon2020NoNo
18005300COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENTJanuary 2023December 2025Abandon3510NoNo
17998473KIT OF GEL-FORMING SOLUTIONS INTENDED FOR PREPARATION OF HYDROGEL BASED ON COVALENTLY CROSSLINKED HYDROXYPHENYL DERIVATIVE OF HYALURONAN FOR PREVENTION OF POSTOPERATIVE COMPLICATIONS RELATED TO FORMATION OF COLORECTAL ANASTOMOSIS, USE OF KIT, METHOD OF PREPARATION OF HYDROGEL AND USE THREREOFNovember 2022December 2025Abandon3701NoNo
17982024PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND METHODS OF USING THE SAMENovember 2022October 2024Allow2311NoNo
17967943Transdermal Double-layer Microneedle Based on Hydrogen Producing Probiotics and Its Preparation Method and ApplicationOctober 2022March 2026Abandon4101NoNo
18047180NOVEL PHARMACEUTICAL COMPOSITIONOctober 2022May 2025Abandon3021NoNo
17917160CRYSTALLINE FORMS OF 3-CYANO-1-[4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL]-1H-PYRAZOL-1-YL]CYCLOBUTANEACETONITRILE, AND USE THEREOFOctober 2022May 2025Allow3110NoNo
17936733COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKINSeptember 2022September 2023Abandon1201NoNo
17995025COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTIONSeptember 2022October 2025Abandon3701NoNo
17915021COMPOSITION COMPRISING ANTIMICROBIAL AGENT AND ITS USESSeptember 2022September 2025Abandon3601NoNo
17906473MICROCAPSULES COATED WITH A POLYSUCCINIMIDE DERIVATIVESeptember 2022December 2025Allow3921YesNo
17943998Self-Warming Hygienic TissueSeptember 2022October 2024Abandon2520YesNo
17941093MEDICAL GRADE NANOFIBRILLAR CELLULOSE HYDROGEL, A METHOD FOR TREATING A SUBJECT IN NEED OF TREATMENT OF BODY WITH IMPLANTABLE MATERIAL AND A METHOD FOR MANUFACTURING THE MEDICAL GRADE NANOFIBRILLAR CELLULOSE HYDROGELSeptember 2022March 2025Abandon3021NoNo
17895951SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITORAugust 2022May 2024Abandon2001NoNo
17820781METHOD OF MANUFACTURING PHARMACEUTICAL COMPOSITIONSAugust 2022August 2023Abandon1210NoNo
17881390ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB AND IN VITRO CHARACTERIZATION THEREOFAugust 2022October 2024Abandon2620YesNo
17814128DELIVERY OF BIOLOGICS VIA MINERAL CRYSTALS FOR REGENERATIVE MEDICINE APPLICATIONSJuly 2022December 2025Abandon4111NoNo
17861204ENVIRONMENTALLY BIODEGRADABLE MICROCAPSULESJuly 2022November 2024Allow2811YesNo
17838344ORAL NOURISHING COMPOSITION AND METHODS THEREOFJune 2022July 2025Abandon3701NoNo
17731905POROUS SILICATE AND/OR ALUMINOSILICATE MATRIX/CERIUM OXIDE NANOPARITLE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERYApril 2022September 2024Allow2921YesNo
17724166RESIN COMPOSITIONS COMPRISING A MACROMOLECULE CROSSLINKED WITH POLYAMIDE EPICHLOROHYDRIN, CONTROLLED RELEASE PARTICLES AND COMPOSITIONS COMPRISING SAME, AND METHODS OF MAKING SAMEApril 2022April 2025Abandon3631YesNo
17724141MICROCAPSULES COMPRISING NATURAL MATERIALSApril 2022November 2023Allow1911NoNo
17720656SUGAR COMPOSITIONS FOR TABLETING BY DIRECT COMPRESSIONApril 2022February 2024Allow2220NoNo
17712741POLYUREA CAPSULES PREPARED WITH A POLYISOCYANATE AND CROSS-LINKING AGENTApril 2022October 2023Abandon1811NoNo
17763470ADHESIVE SILICONE PATTERN MATERIAL, AND WEAR COMPRISING SAMEMarch 2022October 2025Abandon4310NoNo
17684954FORMULATIONS OF A COMPOUND MODULATING KINASESMarch 2022September 2023Abandon1810NoNo
17639385MICROCAPSULE AND HAIR CARE COMPOSITIONMarch 2022September 2024Allow3130NoNo
17581665SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODSJanuary 2022May 2023Allow1610NoNo
17573235COMPOSITIONS AND METHODS FOR INTRACELLULAR IRON DISPLACEMENT PROTEINSJanuary 2022March 2024Abandon2620YesNo
17566752MESOPOROUS SPONGE SPICULE AND METHODS THEREOFDecember 2021June 2025Allow4130YesNo
17561782EXTENDED RELEASE GASTRORETENTIVE FORMULATION AGAINST HELICOBACTER PYLORIDecember 2021June 2025Abandon4201NoNo
17619641COMPOSITION FOR SKIN WHITENING, COMPRISING CARVONE OR SALT THEREOF AS ACTIVE INGREDIENTDecember 2021November 2023Abandon2310NoNo
17644612PHARMACEUTICAL COMPOSITION, COMPRISING PHOSPHATE BINDER PARTICLESDecember 2021August 2022Allow710NoNo
17644599METHOD OF MANUFACTURING PHARMACEUTICAL COMPOSITIONSDecember 2021August 2022Allow710NoNo
17596509PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL CONTAINING XYLOGLUCAN AND ALCOHOLS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTSDecember 2021April 2025Abandon4031NoNo
17615122CELL ACTIVATOR OF ANIMAL CELLNovember 2021September 2025Allow4511YesNo
17614644FILM-FORMING COMPOSITION CONTAINING GELLAN GUM AND STARCH, AND APPLICATION IN SOFT CAPSULENovember 2021February 2026Allow5151YesNo
17613652METHODS OF TREATING URINARY SYSTEM CANCERSNovember 2021January 2026Abandon5020NoNo
17611659HYDROGEL FOR IN-VIVO RELEASE OF MEDICATIONNovember 2021April 2025Allow4011YesNo
17454677SURFACE TREATMENT ARTICLES, DEVICES AND METHODS FOR MAKING THE SAMENovember 2021November 2024Abandon3621NoNo
17610810METHOD OF MANUFACTURING ANTIVIRAL FIBER PRODUCT AND ANTIVIRAL MASK CONTAINING THE PRODUCTNovember 2021March 2025Abandon4001NoNo
17517816ENVIRONMENTALLY BIODEGRADABLE MICROCAPSULESNovember 2021February 2024Abandon2721NoNo
17594878Oral Compositions And Methods Of UseNovember 2021December 2024Abandon3701NoNo
17504913SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODSOctober 2021May 2022Allow710YesNo
17499511UTILIZATION OF BLOOD COMPONENT-CONTAINING SOLUTIONS FOR BIOPROSTHETIC VALVE MANUFACTURE AND TESTINGOctober 2021November 2025Abandon4911NoNo
17602814COSMETIC PRODUCT FOR HAIR CAREOctober 2021January 2025Abandon3910NoNo
17601881HYALURONIC ACID-BASED DISSOLVING FILM, PRODUCTION METHOD THEREOF, AND RELEASE LINER USED FOR THE SAMEOctober 2021March 2025Allow4111NoNo
17601401METHOD FOR TREATING KERATIN MATERIALOctober 2021October 2024Allow3710YesNo
17601011METHOD FOR TREATING KERATIN MATERIALOctober 2021November 2024Abandon3710NoNo
17473180POLYUREA AND POLY(BETA-AMINO ESTER) CAPSULES WITH ENHANCED DEGRADABILITYSeptember 2021November 2023Allow2621YesNo
17438064METHOD FOR IMPROVING THE PERFORMANCE OF A FRAGRANCE OR A FRAGRANCE MIXTURESeptember 2021September 2024Abandon3621YesNo
17472384TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGSSeptember 2021April 2023Abandon1910NoNo
17437067Hyaluronic Acid Derivatives for Wound HealingSeptember 2021April 2025Abandon4311NoNo
17431238POLYURETHANE FOR COSMETIC PREPARATIONS, AND METHOD FOR PRODUCING POLYURETHANE FOR COSMETIC PREPARATIONSAugust 2021January 2025Abandon4111NoNo
17374986Edible Graphic Drug Delivery System and Method of ManufactureJuly 2021July 2023Abandon2410NoNo
17370615TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD)July 2021September 2023Allow2620NoNo
17351338CANNABINOID SYRUP AND METHODS FOR MAKING AND USING SAMEJune 2021January 2025Abandon4340NoNo
17416099PROTEIN MICROCAPSULES AND METHOD OF PREPARING THE SAMEJune 2021May 2025Allow4721YesNo
17416084MICROCAPSULE COMPOSITIONSJune 2021December 2024Allow4211NoNo
17416080GUAR GUM MICROCAPSULESJune 2021May 2025Allow4721NoNo
17416085MICROCAPSULE COMPOSITIONS PREPARED FROM POLYSACCHARIDESJune 2021March 2024Allow3320YesNo
17416090HYDROXYETHYL CELLULOSE MICROCAPSULESJune 2021February 2025Allow4411NoNo
17416096MICROCAPSULES PREPARED FROM PROTEINSJune 2021September 2025Allow5121NoNo
17414663COMPOSITIONJune 2021December 2024Abandon4221YesNo
17304181SKIN LIGHTENING COMPOSTIONSJune 2021January 2025Abandon4340NoYes
17346402Method of Dispersing Hydrophobic Substances in Aqueous Cleansing SystemJune 2021January 2024Abandon3120NoNo
17299198PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPAREDJune 2021April 2025Abandon4721NoNo
17328548ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIBMay 2021November 2022Allow1830YesNo
17328685SEMI-SOLID TOPICAL COMPOSITION CONTAINING PIRFENIDONE AND MODIFIED DIALLYL DISULFIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNEMay 2021May 2023Allow2420NoNo
17328041CANCER TREATMENTMay 2021March 2023Abandon2201NoNo
17307466TEXTURIZED INSECTICIDAL FORMULATIONMay 2021October 2024Abandon4140YesNo
17245360Stem Cell Stimulating Compositions for Treatment of MelasmaApril 2021September 2023Allow2920NoNo
17240363BIOERODIBLE DRUG DELIVERY IMPLANTSApril 2021December 2024Allow4331NoNo
17238037TOPICAL PREPARATIONS OF DRUG DELIVERY FOR NASAL AND SINUS IRRIGATIONApril 2021August 2024Abandon4030YesNo
17287337DRUG CONJUGATE PREPARED USING ALDEHYDE GROUP AT END OF HYALURONIC ACIDApril 2021April 2025Abandon4821NoNo
17286089COMPOSITION AND METHODS FOR IMPARTING A LIKING, CARING OR FRESH ATTRIBUTEApril 2021January 2025Abandon4521YesNo
17285796COMPOSITE FABRIC OF WATER RETENTIVE AND ANTIMICROBIAL MATERIALS FOR SUSTAINED SKIN HYDRATIONApril 2021June 2024Abandon3810NoNo
17285181TRANSDERMAL TROPANE COMPOSITIONS AND METHODS FOR USING THE SAMEApril 2021June 2024Abandon3801NoNo
17282430COMPOSITIONS AND METHODS FOR PROMOTING AND MAINTAINING ORAL HEALTHApril 2021November 2024Abandon4420NoNo
17282089SLURRY AND SOLUTION COMPOSITIONSApril 2021May 2023Abandon2510NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PHAN, DOAN THI-THUC.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
32
Examiner Affirmed
23
(71.9%)
Examiner Reversed
9
(28.1%)
Reversal Percentile
44.0%
Lower than average

What This Means

With a 28.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
91
Allowed After Appeal Filing
23
(25.3%)
Not Allowed After Appeal Filing
68
(74.7%)
Filing Benefit Percentile
36.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PHAN, DOAN THI-THUC - Prosecution Strategy Guide

Executive Summary

Examiner PHAN, DOAN THI-THUC works in Art Unit 1613 and has examined 634 patent applications in our dataset. With an allowance rate of 42.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner PHAN, DOAN THI-THUC's allowance rate of 42.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PHAN, DOAN THI-THUC receive 2.74 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PHAN, DOAN THI-THUC is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by PHAN, DOAN THI-THUC. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.6% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 29.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 31% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 54.9% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.3% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.